1. Home
  2. MRKR

MRKR

Marker Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Founded: N/A Country:
United States
United States
Employees: 8 City: HOUSTON
Market Cap: 38.4M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 20.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.94 EPS Growth: N/A
52 Week Low/High: $0.76 - $9.68 Next Earning Date: 05-13-2024
Revenue: $3,311,133 Revenue Growth: -5.76%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: